Acetaminophen/Hydrocodone Bitartrate

Misuse doesn’t always look dramatic. It may start with taking a slightly higher dose than prescribed or holding onto leftover pills for later use. NEW YORK, NY, UNITED STATES, September 3, 2025 / EINPresswire.com / -- Ascendant Detox Drug & Alcohol Rehab NYC , a boutique detox and outpatient treatment center in Manhattan, is raising awareness about the growing misuse of prescription medications and the dangers tied to long-term dependence. While these drugs are designed to help manage conditions like chronic pain, anxiety, or ADHD, their potential for misuse has fueled a steady rise in treatment admissions over the past twenty years. Prescription medications can be essential, even lifesaving, when taken as directed. But certain drug classes—opioids, benzodiazepines, and stimulants—are also among the most addictive. Opioids such as OxyContin ® and Vicodin ® are often prescribed after surgery or for cancer-related pain, yet they remain a leading driver of addiction. Benzodiazepines like Xanax ® and Valium ® are widely used to treat anxiety and insomnia, but extended use can lead to memory problems, sedation, and dependence. Stimulants such as Adderall ® and Ritalin ® , prescribed for ADHD, are sometimes misused for their energizing effects. Misuse doesn’t always look dramatic. It may start with taking a slightly higher dose than prescribed or holding onto leftover pills for later use. In other cases, individuals crush and snort medications to intensify the effects, which significantly increases the risk of overdose, organ damage, or death. At Ascendant Detox – NYC, clinicians work with clients to address prescription drug dependence through personalized care plans. Services include: Medically supervised detox to help clients withdraw safely. Residential and outpatient therapy addressing both substance use and co-occurring mental health issues. Evidence-based approaches such as Cognitive Behavioral Therapy (CBT), Motivational Interviewing (MI), and trauma-informed care. Holistic therapies including mindfulness practices, art therapy, and group counseling to support long-term recovery. The team also stresses that prescription drug addiction doesn’t always stem from misuse. Some patients follow medical guidance closely, only to realize months or years later that their bodies have become dependent. Warning signs—such as escalating cravings, noticeable mood swings, or “doctor shopping” to obtain multiple prescriptions—can indicate when it’s time to seek help. About Ascendant Detox – NYC Ascendant Detox – NYC is an independent boutique detox and outpatient treatment center in Manhattan. Since 2018, the center has provided compassionate, evidence-based care for individuals seeking recovery from substance use disorders. Committed to safety, privacy, and individualized treatment, Ascendant offers both medical and holistic approaches to help clients build lasting recovery. Admission Office Ascendant Detox Drug & Alcohol Rehab NYC +1 (917) 456-9288 email us here Visit us on social media: LinkedIn Instagram Facebook YouTube X Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

2025年8月5日，Vertex Pharmaceuticals公司宣布，其在研的非阿片类止痛药VX-993在治疗拇囊炎切除术后急性疼痛的二期临床试验中未能达到主要终点。 受此消息影响，Vertex公司股价盘前大跌13%！ 该试验是一项双盲、安慰剂对照研究，共招募了367名接受拇囊炎切除手术的患者。试验测试了三种口服剂量的VX-993（180/90毫克、70/35毫克和10/5毫克），并评估了它们与安慰剂相比减轻术后急性疼痛的能力。 试验结果 在一项涉及 367 人的研究中，术后48小时内，该药物的三种剂量均未显著优于安慰剂。尽管较高剂量在数值上表现较好，但其效果仍逊于服用常见止痛药氢可酮/对乙酰氨基酚（商品名：维柯丁）的患者组。 最常见的不良事件包括恶心、头晕、头痛和呕吐。这表明VX-993在安全性方面表现良好，但其疗效仍需进一步优化。 基于这些结果，公司不再将VX-993作为急性疼痛的单一疗法进行研究。该公司还在进行VX-993用于糖尿病周围神经病变（一种慢性疼痛）的二期临床试验，计划招募约300名患者。 图源：https://www.biopharmadive.com/news/vertex-pain-non-opioid-drug-fda-approval-journavx/738721/ 此外，不再计划对已获批的Nav1.8抑制剂 Journavx 进行治疗坐骨神经痛的三期临床试验。这一决定是在美国食品药品监督管理局告知该公司“他们看不到”获得外周神经性疼痛（包括糖尿病周围神经病变等慢性疼痛）广泛适应症的途径之后做出的。 结束语： VX-993是Vertex公司开发的下一代Nav1.8钠通道抑制剂，旨在通过选择性抑制Nav1.8通道来阻断外周神经系统中的疼痛信号传递。此前，Vertex的另一款Nav1.8抑制剂VX-548已获得美国FDA批准用于治疗中度至重度急性疼痛，并显示出良好的疗效和安全性。一日两款Nav1.8抑制剂遭双杀，Vertex想要突破更多的疼痛适应症还有漫长的路要走。